Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Tikcro reports net loss of $1.0 million for third quarter 2011

Tikcro Technologies Ltd. today reported results for the third quarter and nine months ended September 30, 2011.

18 Nov 2011

Researchers plan joint clinical trials of new cancer treatments, personalized therapies

The Virginia G. Piper Cancer Center at Scottsdale Healthcare is expanding its efforts to accelerate advances in cancer care with the addition of Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute in Los Angeles as a collaborator in clinical trials to develop personalized therapies that could lead to more effective cancer treatments.

9 Nov 2011

TERE1 gene mutation also contributes to invasive bladder cancer

Research conducted by Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology at LSU Health Sciences Center New Orleans, and colleagues has found that a defect in a gene involved in a rare disease of the cornea also contributes to the progression of invasive bladder cancer.

2 Nov 2011

TJUH offers new optical imaging agent for bladder cancer detection

Thomas Jefferson University Hospital is one of a select number of medical centers nationwide—and currently the only one in the Northeast—offering a newly approved optical imaging agent for the detection of papillary cancer of the bladder in patients with known or suspected bladder cancer.

21 Oct 2011

OncoGenex commences enrollment in OGX-427 Phase II trial for bladder cancer

OncoGenex Pharmaceuticals, Inc. announced today that it has initiated patient enrollment in a randomized, Phase II clinical trial evaluating OGX-427, an inhibitor of heat shock protein 27 (Hsp27), in patients with advanced bladder cancer.

21 Oct 2011

Dendreon initiates enrollment in DN24-02 Phase 2 trial for HER2 positive cancer

Dendreon Corporation today announced that the company has begun enrolling patients into a Phase 2 trial for DN24-02, Dendreon's investigational active cellular immunotherapy being evaluated for the treatment of HER2 positive cancer.

18 Oct 2011

FDA grants Advaxis pre-IND meeting for ADXS-HER2 cancer immunotherapy

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.

12 Oct 2011

Latest findings on cancer to be presented at 10th AACR international conference

What: The 10th AACR International Conference on Frontiers in Cancer Prevention Research will bring together scientists to share the latest findings in genetics, chemoprevention and lifestyle choices that may prevent cancer.

4 Oct 2011

Kimmel Cancer Center at Jefferson celebrates two decades of caring and collaboration to beat cancer

From October forward, the Kimmel Cancer Center at Jefferson (KCC), a National Cancer Institute-designated cancer center, is celebrating 20 years of service to the community and the groundbreaking cancer research from the scientists and physicians who've provided an invaluable contribution to medical science and healthcare.

30 Sep 2011

Photocure, Ipsen partner to commercialise Hexvix for diagnosis of bladder cancer

Ipsen announces today a partnership with Photocure, a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology.

27 Sep 2011

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Aeterna Zentaris Inc., today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.

26 Sep 2011

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin, adenoviral VEGF-C growth factor therapy, was successful in rebuilding lymphatic vessels in pre-clinical animal models.

26 Sep 2011

One in five cancer patients more likely to develop venous thromboembolism

An analysis of more than 30,000 cancer patients has shown that blood clots are a more common complication than doctors may realize, causing additional hospitalizations and driving up the cost of care, according to a study led by a Duke Cancer Institute researcher.

21 Sep 2011

Roxon plans to propagate tough stands on tobacco packaging

Health Minister Nicola Roxon plans to encourage other countries to follow Australia's push for plain-packaged tobacco at a major United Nations summit on chronic diseases today.

19 Sep 2011

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Aeterna Zentaris Inc. earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.

14 Sep 2011

Tengion reinitiates enrollment in Neo-Urinary Conduit clinical trial for bladder cancer

Tengion, Inc. today announced that it has reinitiated enrollment of patients in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit, which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal.

14 Sep 2011

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Aeterna Zentaris Inc. today announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency.

31 Aug 2011

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

Aeterna Zentaris Inc. today announced that a poster on its novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado.

30 Aug 2011

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

29 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Tikcro reports net loss of $1.0 million for third quarter 2011

Researchers plan joint clinical trials of new cancer treatments, personalized therapies

TERE1 gene mutation also contributes to invasive bladder cancer

TJUH offers new optical imaging agent for bladder cancer detection

OncoGenex commences enrollment in OGX-427 Phase II trial for bladder cancer

Dendreon initiates enrollment in DN24-02 Phase 2 trial for HER2 positive cancer

FDA grants Advaxis pre-IND meeting for ADXS-HER2 cancer immunotherapy

Latest findings on cancer to be presented at 10th AACR international conference

Kimmel Cancer Center at Jefferson celebrates two decades of caring and collaboration to beat cancer

Photocure, Ipsen partner to commercialise Hexvix for diagnosis of bladder cancer

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

One in five cancer patients more likely to develop venous thromboembolism

Roxon plans to propagate tough stands on tobacco packaging

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Tengion reinitiates enrollment in Neo-Urinary Conduit clinical trial for bladder cancer

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

MDxHealth first half 2011 commercial revenues increase 19%

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Newsletters you may be interested in